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Abstract
Background: The Australian paralysis tick, Ixodes holocyclus, causes paralysis predominantly in dogs and cats in the
Eastern coastal regions of Australia. Rapid onset of effect of a parasiticide is critical to minimize the deleterious
effects of these tick infestations, especially tick paralysis caused by the salivary neurotoxin. The speed of kill of a
novel orally administered isoxazoline parasiticide, sarolaner chewable tablets (Simparica®), against I. holocyclus on
dogs was evaluated and compared with afoxolaner (NexGard®) for 5 weeks after a single oral dose.
Methods: Twenty-four (24) dogs were randomly allocated to treatment with either placebo, sarolaner (label dose of
2 to 4 mg/kg as per dosing table), or afoxolaner (label dose of 2.7 to 6.9 mg/kg) based on pre-treatment body
weights. Following artificial infestation on Day -1, dogs were examined and live ticks counted at 8, 12, 24 and 48 h
after treatment on Day 0, and at 12, 24 and 48 h after subsequent re-infestations on Days 7, 14, 21, 28 and 35.
Efficacy was determined at each time point relative to counts for placebo dogs based on geometric means.
Results: At 8 and 12 h time points on Day 0, sarolaner-treated dogs had significantly lower geometric mean tick counts
compared to the dogs treated with afoxolaner (P≤ 0.0303). Efficacy of sarolaner against an existing infestation was 86.2
and 96.9% compared with that of afoxolaner which had efficacy of 21.3 and 85.0% at 8 and 12 h time points, respectively.
Against subsequent weekly re-infestations at 12 h time points, treatment with sarolaner resulted in significantly lower
geometric mean tick counts than afoxolaner-treated dogs on all days (P≤ 0.0077) with the efficacy ranging from 60.2 to
92.2%, compared to 5.8 to 61.0% in the afoxolaner-treated dogs. Against subsequent weekly re-infestations at the 24 h
time points on Days 22 and 36, efficacy of sarolaner was significantly higher at 99.2 and 97.9%, respectively, compared
with afoxolaner which had efficacy of 92.4 and 91.9% (P≤ 0.0356). At the 48 h time points following each of the five
weekly re-infestations, the mean efficacy results of sarolaner and afoxolaner treated dogs were similar on most occasions.
There were no adverse reactions to treatments.
Conclusions: In this controlled laboratory evaluation, a single dose of sarolaner had a significantly faster speed of kill
against an existing infestation of I. holocyclus, than afoxolaner at 8 and 12 h post-treatment. The rapid and consistent kill
of ticks provided by sarolaner within 24 h after a single oral dose and following weekly re-infestations over 35 days
suggests this treatment will provide highly effective, rapid and reliable control of ticks over the entire treatment interval,
thereby minimizing the risk of tick paralysis in dogs.
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Background
Ixodes holocyclus, also known as the paralysis tick in
Australia, causes tick paralysis in domestic animals, a
potentially-lethal disease seen predominantly in dogs and
cats [1–3], horses [4–6] and humans [7–9]. Ixodes holocy-
clus is widely distributed along the eastern coastal regions
of Australia from North Queensland to Lakes Entrance of
Victoria [1, 10–12]. The majority of cases of tick paralysis
in dogs are reported during spring to early summer due to
favorable climate [1, 11]. Ixodes holocyclus is suspected as
a vector for transmission of Borrelia burgdorferi (sensu
stricto) [13] and Rickettsia australis [14, 15] in humans,
but it is rarely reported as a vector for transmission of
other pathogens in domestic animals.
Tick paralysis is characterised by progressive ascending
lower motor neuron (LMN) flaccid paralysis caused by the
neurotoxin produced in the salivary glands of the female I.
holocyclus [3, 16]. Clinical manifestations of tick paralysis
have been previously reviewed and well documented and
include flaccid paralysis, cardio-pulmonary complications
and sometimes death [3, 17, 18]. Typically, the onset of
clinical signs usually does not occur until 4 or 5 days after
tick attachment [3, 17, 19]. This coincides with a sudden
increase in the salivary toxin secretions which occur dur-
ing the later stages of tick infestations [3, 16]. The dur-
ation of feeding, rate of growth and release of toxins
however can vary depending on the age of the ticks
and favorable ambient temperature and humidity [20].
The longer the duration of attachment, the greater
the potential risk of paralysis, thus the sooner an at-
tached tick can be removed, the lower the risk of par-
alysis [17, 19]. Therefore, an acaricide with a fast
speed of kill is critical in removing any pre-existing
ticks and minimising the risk of morbidity and mor-
tality due to tick paralysis [21].
Treatment of tick paralysis typically centers around
removal of attached ticks, the neutralization of toxins,
the control of clinical manifestations of tick paralysis
and the treatment of any anaphylactic reactions due to
the administration of tick anti-sera [22]. Successful
treatment outcomes also depend on locating and re-
moving all the attached ticks on the dogs followed by
the administration of an acaricidal agent [23]. A routine
tick search, even by an experienced person, may be un-
successful in locating all ticks, even in the common
predilection sites [20], since ticks can be hidden in
areas such as the nostril, inside the anus and ear canals,
hence an acaricide with a wider systemic distribution
should be the preferred choice of treatment. Systemic
formulations like the new class of isoxazolines offer
wider distribution to all anatomical sites in the body
[21] and are therefore able to provide more reliable
Table 1 Mean live Ixodes holocyclus counts and efficacy relative to placebo at 8, 12, 24 and 48 h after treatment for dogs treated
with a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Tick counting time points post-treatment
8 h 12 h 24 h 48 h
Placebo Range 21–28 20–28 19–28 19–30
Arithmetic mean (AM) 24.13 24.25 23.63 23.75
Geometric mean GM)a 24.00 24.13 23.47 23.53
Sarolaner Range 0–13 0–8 0–0 0–0
Arithmetic mean (AM) 5.13 1.63 0 0
AM Efficacy (%) 78.87 93.30 100 100
Geometric mean (GM)a 3.32 0.76 0 0
GM Efficacy (%) 86.17 96.87 100 100
Test statistic vs placebo t(9) = 5.02 t(8) = 8.65 t(34) = 17.31 t(17) = 58.45
P-value vs placebo 0.0007 < 0.0001 < 0.0001 < 0.0001
Afoxolaner Range 10–28 1–13 0–2 0–0
Arithmetic mean (AM) 20.13 5.00 0.38 0
AM Efficacy (%) 17.01 79.38 98.41 100
Geometric mean (GM)a 18.89 3.63 0.25 0
GM Efficacy (%) 21.28 84.95 98.93 100
Test statistic vs placebo t(9) = 0.65 t(8) = 6.24 t(46) = 11.78 t(17) = 58.45
P-value vs placebo 0.5302 0.0003 < 0.0001 < 0.0001
Test statistic vs sarolaner t(9) = 4.36 t(15) = 2.40 t(70) = 0.74 t(17) = 0.00
P-value vs sarolaner 0.0018 0.0303 0.4622 1.0000
aP-values are based on comparison of geometric means
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efficacy, unlike the topical counterparts [23] which may
not reach all the anatomical sites.
The introduction of isoxazolines such as sarolaner,
afoxolaner and fluralaner has resulted in an improve-
ment in tick control in dogs in recent times.
Sarolaner, a pure form of S-entamioner, is a potent
ectoparaciticide [24] with a broad spectrum of activity
against different tick species [25, 26], including the
Australian paralysis tick, I. holocyclus (Zoetis, unpub-
lished data).
In this laboratory study, the speed of kill of sarolaner
(Simparica®) and afoxolaner (Nexgard®) was evaluated
against existing I. holocyclus infestations and weekly re-
infestations for a period of 5 weeks after treatment with
a single dose.
Methods
The study was a blinded, negative-controlled, random-
ized laboratory efficacy design conducted in New
South Wales, Australia. Study procedures were in
accordance with the World Association for the
Advancement of Veterinary Parasitology (WAAVP)
guidelines for evaluating the efficacy of parasiticides
for the treatment, prevention and control of flea and
tick infestation on dogs and cats [27] and complied
with the principles of Good Clinical Practice [28].
The protocol was reviewed and approved by the Vetx
Research Animal Ethics Committee, NSW. Blinding of
the study was assured through the separation of
functions. All personnel conducting observations, or
performing infestations and counts were blinded to
treatment allocation.
Animals
Twenty-four (24) male and female, Foxhound dogs from 1
to 9 years of age and weighing from 30.1 to 46.9 kg were
used in the study. Each dog was individually identified by a
unique electronic transponder and had undergone an ad-
equate wash-out period to ensure that no residual ectopara-
siticide efficacy remained from any previously administered
treatments. This was confirmed by the tick carrying cap-
acity test results that showed all enrolled dogs had ≥ 21
ticks. Dogs were individually housed in indoor runs such
that no physical contact was possible between them and
they were acclimatized to these conditions for at least 7 days
prior to treatment. Dogs were fed an appropriate mainten-
ance ration of a commercial dry canine feed for the dur-
ation of the study. Water was available ad libitum. All dogs
were given a physical examination to ensure that they were
in good health at enrollment and suitable for inclusion in
the study. General health observations were performed
twice daily throughout the study.
Table 2 Mean live Ixodes holocyclus counts and efficacy relative to placebo at 12 h after weekly re-infestations for dogs treated with
a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Day of study
7 14 21 28 35
Placebo Range 16–28 22–28 17–26 19–27 23–28
Arithmetic Mean (AM) 21.75 25.25 23.75 23.13 25.13
Geometric Mean (GM)a 21.44 25.16 23.56 22.99 25.09
Sarolaner Range 0–12 0–10 0–18 2–21 2–16
Arithmetic mean (AM) 3.00 3.00 4.88 10.75 8.75
AM Efficacy (%) 86.21 88.12 79.47 53.51 65.17
Geometric mean (GM)a 1.67 2.26 3.11 9.15 7.50
GM Efficacy (%) 92.20 91.03 86.78 60.21 70.11
Test statistic vs placebo t(8) = 6.26 t(8) = 8.50 t(8) = 5.41 t(9) = 3.77 t(8) = 4.97
P-value vs placebo 0.0002 < 0.0001 0.0007 0.0048 0.0012
Afoxolaner Range 2–16 7–20 10–22 15–28 16–27
Arithmetic mean (AM) 9.63 12.13 17.63 22.00 21.00
AM Efficacy (%) 55.75 51.98 25.79 4.86 16.42
Geometric mean (GM)a 8.36 11.49 17.03 21.66 20.78
GM Efficacy (%) 61.01 54.31 27.69 5.78 17.17
Test statistic vs placebo t(9) = 3.85 t(10) = 6.26 t(15) = 2.65 t(17) = 0.67 t(15) = 2.30
P-value vs placebo 0.0042 < 0.0001 0.0182 0.5138 0.0366
Test statistic vs sarolaner t(13) = 3.16 t(10) = 5.07 t(9) = 4.37 t(9) = 3.44 t(8) = 4.10
P-value vs sarolaner 0.0077 0.0004 0.0021 0.0070 0.0033
aP-values are based on comparison of geometric means
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Design
The study followed a randomized complete block de-
sign, with pairs of dogs as the experimental unit.
Dogs enrolled in the study were immunised to the
tick toxin- holocylotoxin as described previously [29]
and selected based on acceptable results (tick counts
of ≥ 21) to the tick carrying capacity test performed
on Day -7. Prior to treatment, dogs were ranked ac-
cording to pre-treatment body weights into four
blocks of six (three pairs of dogs). Within each block,
one pair of dogs was randomly allocated to treatment
with placebo, sarolaner, or afoxolaner. There were
eight dogs per treatment group.
Treatment
Body weights collected on Day -5 were used to deter-
mine the appropriate dose to be administered. On
Day 0, dogs received either a placebo tablet, Simpar-
ica® (sarolaner) at the recommended dose of 2 mg/kg
(range: 2 to 4 mg/kg), or NexGard® (afoxolaner) as
per label directions (2.7 to 6.9 mg/kg). All doses were
administered by hand pilling to ensure accurate and
complete dosing. Each dog was observed for at least
2 min after treatment to ensure the dose was
swallowed.
Tick infestation and assessment
The unfed adult female I. holocyclus ticks were collected
from the Northern Rivers region of New South Wales,
Australia approximately 2 months prior to the start of
the study. The ticks were stored in dark conditions at
around 12 °C and high humidity [29]. Tick infestations
were performed on Days -7 (host suitability), -1, 7, 14,
21, 28 and 35. Prior to each infestation, dogs were exam-
ined to ensure they were free of ticks. Each dog was
infested with 30 viable unfed female ticks at pre-defined
locations (head, shoulders, dorsal midline of the body)
on the dogs as described previously [29]. For Day -1 in-
festation, tick counts were performed at 8, 12, 24 and
48 h after treatment on Day 0 and all other tick counts
were performed at 12, 24 and 48 h after each weekly in-
festation. Tick assessments at 8 (only on Day 0), 12 and
24 h time points were performed without removing the
ticks from the dogs. After counting at the 48 h time
point, all ticks were removed. Ticks were characterised
as described previously [29] except moribund ticks were
recorded in a separate category and included in the live
counts in this study for the efficacy calculations.
Statistical analysis
The primary outcome measure was live tick counts.
Data for post-treatment live (free plus attached) tick
Table 3 Mean live Ixodes holocyclus counts and efficacy relative to placebo at 24 h after weekly re-infestations for dogs treated with
a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Day of study
8 15 22 29 36
Placebo Range 17–27 20–28 15–26 19–26 19–26
Arithmetic Mean (AM) 21.00 24.13 23.75 22.25 22.88
Geometric Mean (GM)a 20.70 23.95 23.44 22.13 22.78
Sarolaner Range 0–6 0–1 0–3 0–3 0–3
Arithmetic mean (AM) 1.75 0.25 0.38 1.25 0.75
AM Efficacy (%) 91.67 98.96 98.42 94.38 96.72
Geometric mean (GM)a 1.26 0.19 0.19 0.96 0.49
GM Efficacy (%) 93.93 99.21 99.19 95.67 97.86
Test statistic vs placebo t(34) = 12.26 t(34) = 16.48 t(34) = 16.37 t(34) = 13.37 t(34) = 15.01
P-value vs placebo < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Afoxolaner Range 0–5 0–1 0–6 0–5 0–8
Arithmetic mean (AM) 2.00 0.25 2.75 1.75 2.75
AM Efficacy (%) 90.48 98.96 88.42 92.13 87.98
Geometric mean (GM)a 1.41 0.19 1.78 1.14 1.85
GM Efficacy (%) 93.17 99.21 92.42 94.87 91.89
Test statistic vs placebo t(46) = 8.70 t(46) = 12.06 t(46) = 8.62 t(46) = 9.44 t(46) = 8.41
P-value vs placebo < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Test statistic vs sarolaner t(70) = 0.22 t(70) = 0.00 t(70) = 2.80 t(70) = 0.29 t(70) = 2.14
P-value vs sarolaner 0.8247 1.0000 0.0066 0.7757 0.0356
aP-values are based on comparison of geometric means
Packianathan et al. Parasites & Vectors  (2017) 10:98 Page 4 of 8
counts were summarized with arithmetic (AM) and
geometric (GM) means by treatment group and time
point. Tick counts were transformed by the loge(-
count + 1) transformation prior to analysis in order
to stabilize the variance and normalize the data.
Using the PROC MIXED procedure (SAS 9.3, SAS
Institute Inc., Cary, NC, USA), transformed counts
were analyzed using a mixed linear model for re-
peated measures for the 12, 24 and 48 h time points
separately. The fixed effects were treatment, time
point and the interaction between time point and
treatment. The random effects included block, pair,
animal, block by treatment by time point interaction,
and error. The data for the 8 h time point (Day 0
only) were analysed with terms including the fixed
effect of treatment group and the random effects of
block, pair and error. Testing was two-sided at the
significance level α = 0.05, with tests based on con-
trasts between treatment least squares means from
the fitted models.
The assessment of efficacy for live ticks was based on
the percent reduction in the AM and GM live tick
counts for the treated groups relative to placebo, as
suggested by the most recent guidelines of the WAAVP
for systemic acaricides [27], and was calculated using
Abbott’s formula:
% reduction ¼ 100
 mean count placeboð Þmean count treatedð Þ
mean count placeboð Þ
As the distribution of parasite counts within each
group was likely be skewed, comparison between groups
was primarily based on GM live tick counts [27].
Results
There were no treatment-related adverse events during
the study. Placebo-treated dogs maintained good tick in-
festations throughout the study with individual tick
counts ranging from 15 to 30 (Tables 1, 2, 3 and 4).
Against an existing infestation, at the 8 and 12 h time
points, treatment with sarolaner resulted in significantly
lower GM tick counts compared to both placebo (P ≤
0.0007) and afoxolaner treated dogs (P ≤ 0.0303). There
was no significant difference between the GM live tick
counts at 8 h for the afoxolaner and placebo-treated
dogs (P = 0.5302). Efficacy of sarolaner against an exist-
ing infestation was 86.2 and 96.9% compared with that
of afoxolaner which had efficacy of 21.3 and 85.0% at 8
and 12 h time points respectively. Efficacy of sarolaner
and afoxolaner reached 100% at 24 and 48 h post-
treatment respectively (Table 1 and Fig. 1).
Table 4 Mean live Ixodes holocyclus counts and efficacy relative to placebo at 48 h after weekly re-infestations for dogs treated with
a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Day of study
9 16 23 30 37
Placebo Range 17–26 20–28 15–26 21–27 19–26
Arithmetic mean (AM) 21.00 24.13 22.00 22.88 22.25
Geometric mean (GM)a 20.79 23.98 21.69 22.80 22.15
Sarolaner Range 0–0 0–2 0–2 0–3 0–1
Arithmetic mean (AM) 0 0.38 0.50 1.25 0.25
AM Efficacy (%) 100 98.45 97.73 94.54 98.88
G. mean (GM)a 0 0.25 0.32 1.03 0.19
GM Efficacy (%) 100 98.95 98.54 95.48 99.15
Test statistic vs placebo t(19) = 54.50 t(25) = 20.30 t(19) = 13.13 t(23) = 12.78 t(26) = 21.67
P-value vs placebo < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Afoxolaner Range 0–0 0–1 0–4 0–2 0–1
Arithmetic mean (AM) 0 0.13 1.50 0.38 0.25
AM Efficacy (%) 100 99.48 93.18 98.36 98.88
G. mean (GM)a 0 0.09 1.28 0.25 0.19
GM Efficacy (%) 100 99.62 94.12 98.90 99.15
Test statistic vs placebo t(19) = 54.50 t(25) = 21.23 t(19) = 10.60 t(23) = 15.29 t(26) = 21.67
P-value vs placebo < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Test statistic vs sarolaner t(19) = 0.00 t(25) = 0.93 t(19) = 2.53 t(23) = 2.51 t(26) = 0.00
P-value vs sarolaner 1.0000 0.3606 0.0204 0.0195 1.0000
aP-values are based on comparison of geometric means
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Against subsequent weekly infestations at the 12 h
time points, treatment with sarolaner resulted in signifi-
cantly lower GM tick counts compared to both placebo-
(P ≤ 0.0048) and afoxolaner-treated dogs (P ≤ 0.0077) on
all Days (7, 14, 21, 28 and 35). Efficacy of sarolaner at
the 12 h time points following weekly re-infestations
ranged from 60.2 to 92.2% compared to 5.8 to 61.0% in
the afoxolaner treated dogs (Table 2 and Fig. 2).
Against subsequent weekly infestations at the 24 h time
points on days 22 and 36, sarolaner-treated dogs had sig-
nificantly lower GM tick counts than afoxolaner-treated
dogs (P ≤ 0.0356). On Days 8, 15, 22, 29 and 36, treatment
with sarolaner and afoxolaner resulted in significantly
lower GM tick counts than placebo (P ≤ 0.0001). At 24 h
following weekly re-infestations, efficacy of sarolaner
ranged from 93.9 to 99.2% compared to 91.9 to 99.2% in
the afoxolaner-treated dogs (Table 3 and Fig. 2).
Against weekly infestations, at the 48 h time points treat-
ment with sarolaner and afoxolaner resulted in significantly
lower GM tick counts than placebo (P ≤ 0.0001) and
efficacy (GM) of sarolaner and afoxolaner treated dogs
were ≥ 95.5% and ≥ 94.1% respectively (Table 4 and Fig. 2).
Discussion
A single dose of sarolaner resulted in the rapid reduction
of an existing infestation of live I. holocyclus ticks with
an efficacy of 86.2% at 8 h and 96.9% at 12 h post-
treatment and the rapid kill of re-infestations for 5 weeks
after treatment within 12 h of attachment with an effi-
cacy of ≥ 60.2%. Although the onset of tick paralysis
Fig. 2 Percent efficacy based on geometric mean counts relative to placebo at 12, 24 and 48 h after weekly post-treatment re-infestations of
Ixodes holocyclus for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0
Fig. 1 Percent efficacy based on geometric mean counts relative to placebo at 8, 12, 24 and 48 h after treatment for dogs treated with a single
oral dose of sarolaner or afoxolaner on Day 0
Packianathan et al. Parasites & Vectors  (2017) 10:98 Page 6 of 8
typically does not occur until day 4 or 5 after tick attach-
ment, the sooner an attached tick can be killed, the
lower the risk of paralysis [3, 17, 19], especially those
pre-existing ticks that have already been on the dogs for
3–4 days prior to treatment. The rapid speed of kill of
sarolaner as early as 8 h against an existing infestation
will provide faster removal of attached ticks, thereby
minimising the risk of tick paralysis. Similar faster speed
of kill of sarolaner has also been demonstrated against
other Ixodes tick species such as Ixodes scapularis and
Ixodes ricinus [30, 31]. The faster speed of kill and per-
sistent efficacy of sarolaner will provide excellent overall
efficacy against I. holocyclus for up to 5 weeks.
Conclusions
Sarolaner had a significantly faster speed of kill at both 8
and 12 h compared with afoxolaner against existing in-
fections of paralysis tick and had higher efficacy than
afoxolaner at 12 h after re-infestation over 35 days.
The rapid and consistent kill of ticks provided by saro-
laner within 24 h after a single oral dose and following
weekly re-infestations over 35 days suggests this treat-
ment will provide highly effective, rapid and reliable
control of ticks over the entire treatment interval,
thereby minimizing the risk of tick paralysis in dogs.
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